ORNBV Orion Oyj Class B

Orion is building a unique pharmaceutical research ecosystem in Finland – using data and artificial intelligence to shorten the development time of new innovative medicines

Orion is building a unique pharmaceutical research ecosystem in Finland – using data and artificial intelligence to shorten the development time of new innovative medicines

ORION CORPORATION                 PRESS RELEASE                 30 March 2023 at 9.30 EEST

Orion is building a unique pharmaceutical research ecosystem in Finland – using data and artificial intelligence to shorten the development time of new innovative medicines

Orion is launching a project to build a unique data and AI-based pharmaceutical research ecosystem in Finland in cooperation with other companies, research institutes and universities. Business Finland has granted nearly EUR 10 million in funding to Orion, and reserved nearly EUR 20 million for the research institutes and companies participating in the ecosystem to be created.

The four-year ecosystem project led by Orion aims to reduce the time needed to research and develop new innovative medicines by using artificial intelligence and improving data processing and analysis. Efficient and optimal data use can reduce the pharmaceutical research phase by up to three years compared with the current situation.



The operations of the research ecosystem are based on sharing information and various types of expertise within the network and creating new data to validate novel predictive models. The project will create new competencies by bringing together experts in disease biology, pharmaceutical research and data science. The operating model of the ecosystem to be built during the project will be tested in new drug discovery projects while also creating international business opportunities for the ecosystem companies.



“Artificial intelligence-guided use of data is a competitive advantage when developing new innovative medicines. It improves the probability of success and shortens the discovery and development time significantly. The volume of knowledge is growing continuously, and its optimal use requires more resources and special expertise. Finland has a great deal of high-level knowledge, but expertise is fragmented. By joining forces, Finnish pharmaceutical, biotechnology and technology companies, research institutes and universities can succeed in tough international competition. A well-functioning and thriving pharmaceutical research ecosystem will also attract talent and investment to Finland,” says Outi Vaarala, Head of Orion’s Innovative Medicines division.

Business Finland aims to increase innovation and the competitive advantage of Finnish companies in international markets through partnership funding.



Contact person:

Outi Vaarala, SVP, Innovative Medicines and Research & Development

Orion Corporation

tel. 2        

                                                    

Publisher:

Orion Corporation

Communications

Orionintie 1A, FI-02200 Espoo, Finland

Website:

Orion is a globally operating Finnish pharmaceutical company – a builder of well-being. We develop, manufacture and market human and veterinary pharmaceuticals and active pharmaceutical ingredients. Orion has an extensive portfolio of proprietary and generic medicines and self-care products. The core therapy areas of our pharmaceutical R&D are oncology and pain. Proprietary products developed by Orion are used to treat cancer, neurological diseases and respiratory diseases, among others. Orion’s net sales in 2022 amounted to EUR 1,341 million and the company had around 3,500 employees at the end of the year. Orion’s A and B shares are listed on Nasdaq Helsinki.

 



EN
30/03/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Orion Oyj Class B

 PRESS RELEASE

Orion Group Interim Report January–September 2025

Orion Group Interim Report January–September 2025 ORION CORPORATION INTERIM REPORT 1–9/2025 28 OCTOBER 2025 at 12:00 EET Orion Group Interim Report January–September 2025 July–September 2025 Highlights Net sales totalled EUR 423.2 (July–September 2024: 471.3) million Operating profit was EUR 121.0 (202.0) millionNet sales and operating profit of the comparison period include EUR 130 million of major milestone paymentsBasic earnings per share were EUR 0.68 (1.14)Cash flow from operating activities per share was EUR 0.55 (0.48)The outlook for 2025 has been specified: Net sales are estimat...

 PRESS RELEASE

Orion-konsernin osavuosikatsaus tammi–syyskuu 2025

Orion-konsernin osavuosikatsaus tammi–syyskuu 2025 ORION OYJ OSAVUOSIKATSAUS 1–9/2025 28.10.2025 klo 12:00 Orion-konsernin osavuosikatsaus tammi–syyskuu 2025 Heinä–syyskuu 2025 lyhyesti Liikevaihto oli 423,2 miljoonaa euroa (471,3 miljoonaa euroa 7–9/2024)Liikevoitto oli 121,0 (202,0) miljoonaa euroaVertailukauden liikevaihto ja -voitto sisältävät 130 miljoonaa euroa merkittäviä etappimaksujaLaimentamaton osakekohtainen tulos oli 0,68 (1,14) euroaOsakekohtainen liiketoiminnan rahavirta oli 0,55 (0,48) euroaVuoden 2025 näkymäarviota on täsmennetty: Liikevaihdon arvioidaan olevan 1 640–1 ...

 PRESS RELEASE

49,164 Orion Corporation A shares converted into B shares

49,164 Orion Corporation A shares converted into B shares ORION CORPORATION STOCK EXCHANGE RELEASE – OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE 24 OCTOBER 2025 at 9.00 EEST         49,164 Orion Corporation A shares converted into B shares In accordance with Section 3 of the Articles of Association of Orion Corporation, 49,164 A shares have been converted into 49,164 B shares. The conversion has been entered into the Trade Register on 24 October 2025. The total number of shares in Orion Corporation is 141,134,278 which, after the conversion, consists of 31,841,81...

 PRESS RELEASE

49 164 kpl Orion Oyj:n A-osaketta muunnettu B-osakkeiksi

49 164 kpl Orion Oyj:n A-osaketta muunnettu B-osakkeiksi ORION OYJ        PÖRSSITIEDOTE – MUUT PÖRSSIN SÄÄNTÖJEN NOJALLA JULKISTETTAVAT TIEDOT         24.10.2025 KLO 9.00          49 164 kpl Orion Oyj:n A-osaketta muunnettu B-osakkeiksi Orion Oyj:n yhtiöjärjestyksen 3 §:n nojalla on muunnettu 49 164 A-osaketta 49 164 B-osakkeeksi. Muuntaminen on merkitty kaupparekisteriin 24.10.2025. Orion Oyj:n osakkeiden kokonaismäärä on 141 134 278 kpl. Muuntamisen jälkeen A-osakkeita on 31 841 817 kpl ja B-osakkeita 109 292 461 kpl. Yhtiön osakkeiden tuottama äänimäärä muunnon jälkeen on yhteensä 7...

 PRESS RELEASE

Orion and Abzena announce exclusive commercial license for Abzena’s an...

Orion and Abzena announce exclusive commercial license for Abzena’s antibody ORION CORPORATION PRESS RELEASE 23 OCTOBER 2025 at 15:30 EEST         Orion and Abzena announce exclusive commercial license for Abzena’s antibody Orion Corporation (“Orion”) and Abzena, the leading end-to-end integrated CDMO for complex biologics and bioconjugates, today announced that Orion has obtained an exclusive, focused commercial license to one of Abzena’s monoclonal antibodies (mAbs) that targets a cancer of high clinical unmet need. The antibody will strengthen Orion’s broad oncology-focused drug Resear...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch